Dr Elena De Vita
Lecturer in Synthetic Biology and Biotechnology
School of Biological and Behavioural Sciences, Department of Bio
Queen Mary University of London
Queen Mary University of London
Research
Drug discovery, Covalent inhibitors, Induced proximity, PHOSTACs, Protein phopshatases
Interests
My research involves the development of novel chemical compounds that can help understanding and treating cancer and other debilitating diseases. The use of advanced in vitro models is therefore essential to bring these compounds forward into the drug discovery pipeline.Publications
2024
What is chemical biology?Antolin AA, Aye Y, Bar-Peled L, De Vita E, Dudkina N, Jewett MC, Kiely-Collins H, Mazitschek R and Zhang ZJ
Cell Chemical Biology, Elsevier vol. 31 (9), 1562-1565.
01-09-2024
Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACsShah RR, De Vita E, Sathyamurthi PS, Conole D, Zhang X, Fellows E, Dickinson ER, Fleites CM, Queisser MA, Harling JD and Tate EW
Journal of Medicinal Chemistry, American Chemical Society (Acs) vol. 67 (6), 4641-4654.
13-03-2024
2022
A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell InvasionZhang L, Lovell S, De Vita E, Jagtap PKA, Lucy D, Grocin AG, Kjær S, Borg A, Hennig J, Miller AK and Tate EW
Journal of The American Chemical Society, American Chemical Society (Acs) vol. 144 (49), 22493-22504.
22-11-2022
Identification of the first structurally validated covalent ligands of the small GTPase RAB27AJamshidiha M, Lanyon-Hogg T, Sutherell CL, Craven GB, Tersa M, De Vita E, Brustur D, Pérez-Dorado I, Hassan S, Petracca R, Morgan RM, Sanz-Hernández M, Norman JC, Armstrong A, Mann DJ, Cota E and Tate EW
Rsc Medicinal Chemistry, Royal Society of Chemistry (Rsc) vol. 13 (2), 150-155.
01-01-2022
Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)Zhang Q, Kounde CS, Mondal M, Greenfield JL, Baker JR, Kotelnikov S, Ignatov M, Tinworth CP, Zhang L, Conole D, De Vita E, Kozakov D, McCluskey A, Harling JD, Fuchter MJ and Tate EW
Chemical Communications, Royal Society of Chemistry (Rsc) vol. 58 (78), 10933-10936.
01-01-2022
2021
Blocking Kallikrein 6 promotes developmental myelinationYoon H, Triplet EM, Simon WL, Choi C, Kleppe LS, De Vita E, Miller AK and Scarisbrick IA
Glia, Wiley vol. 70 (3), 430-450.
09-10-2021
Beyond targeted protein degradation: LD·ATTECs clear cellular lipid dropletsDe Vita E, Lucy D and Tate EW
Cell Research, Springer Nature vol. 31 (9), 945-946.
05-08-2021
A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate CancerLovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E, Xu C, Bakker AT, Maneiro M, Tanaka RJ, Bevan CL, Clements JA and Tate EW
Journal of The American Chemical Society, American Chemical Society (Acs) vol. 143 (23), 8911-8924.
04-06-2021
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugsManeiro M, De Vita E, Conole D, Kounde CS, Zhang Q and Tate EW
67-190.
01-01-2021
Development of a fluorogenic ADAMTS-7 substrateSantamaria S, Buemi F, Nuti E, Cuffaro D, De Vita E, Tuccinardi T, Rossello A, Howell S, Mehmood S, Snijders AP and de Groot R
Journal of Enzyme Inhibition and Medicinal Chemistry, Taylor & Francis vol. 36 (1), 2160-2169.
01-01-2021
2020
10 years into the resurgence of covalent drugsDe Vita E
Future Medicinal Chemistry, Taylor & Francis vol. 13 (2), 193-210.
04-12-2020
The Missing Link between (Un)druggable and Degradable KRASDe Vita E, Maneiro M and Tate EW
Acs Central Science, American Chemical Society (Acs) vol. 6 (8), 1281-1284.
03-08-2020
2019
Synthesis and Structure‐Activity Relationships of N‐(4‐Benzamidino)‐Oxazolidinones: Potent and Selective Inhibitors of Kallikrein‐Related Peptidase 6De Vita E, Smits N, van den Hurk H, Beck EM, Hewitt J, Baillie G, Russell E, Pannifer A, Hamon V, Morrison A, McElroy SP, Jones P, Ignatenko NA, Gunkel N and Miller AK
Chemmedchem, Wiley vol. 15 (1), 79-95.
18-11-2019
Design and Synthesis of Ionic Liquid‐Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI‐Coated Gold NanoparticlesD'Andrea F, Nuti E, Becherini S, Cuffaro D, Husanu E, Camodeca C, De Vita E, Zocchi MR, Poggi A, D'Arrigo C, Cappello V, Gemmi M, Nencetti S, Chiappe C and Rossello A
Chemmedchem, Wiley vol. 14 (6), 686-698.
14-02-2019
2018
Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular ActivityDe Vita E, Schüler P, Lovell S, Lohbeck J, Kullmann S, Rabinovich E, Sananes A, Heßling B, Hamon V, Papo N, Hess J, Tate EW, Gunkel N and Miller AK
Journal of Medicinal Chemistry, American Chemical Society (Acs) vol. 61 (19), 8859-8874.
13-09-2018
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringSananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES and Papo N
Journal of Biological Chemistry, Elsevier vol. 293 (33), 12663-12680.
22-06-2018
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometryLonguespée R, Wefers AK, De Vita E, Miller AK, Reuss DE, Wick W, Herold-Mende C, Kriegsmann M, Schirmacher P, von Deimling A and Pusch S
Acta Neuropathologica Communications, Springer Nature vol. 6 (1)
02-03-2018
Grants
Development of covalent probes for protein phosphatase 1 (PP1)Elena De Vita
£11,000 Royal Society
31-03-2024 - 30-03-2026
Covalent PHOSTACs for targeted protein dephosphorylation against K-Ras driven tumoursElena De Vita
£69,401 Royal Society
01-03-2024 - 31-08-2025